NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Closure of Trading Window03-08-2020
NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 30 June 2020
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2020 ,inter alia, to consider and approve To consider Un-audited Financial Results for the quarter ended June 30, 2020, To consider interim dividend, if any, for the financial year 2020-2103-08-2020
Stock picks by Sameet Chavan of Angel Broking: Buy Natco Pharma, IRB Infra
The entire pharma space has been in limelight since the coronavirus pandemic outbreak27-07-2020
NATCO PHARMA LTD. - 524816 - Related Party Transactions For The FY Ended 2019-2020
Related Party Transactions for the FY ended 2019-202015-07-2020
Natco Pharma settles dispute with Celgene in Canada
Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Ltd, has entered into a settlement agreement with Celgene (now part of Bristol-Myers10-07-2020
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO settles on Lenalidomide for Canada10-07-2020
NATCO PHARMA LTD. - 524816 - Shareholding for the Period Ended June 30, 2020
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here08-07-2020
NATCO PHARMA LTD. - 524816 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- M ADINARAYANADesignation :- Company Secretary and Compliance Officer08-07-2020
NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 202008-07-2020
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and year ended 31st March, 202003-07-2020